Oncologists May Be Ignoring the Cardiovascular Side Effects of Tasigna

Oncologists are thrilled with Tasigna's cancer-fighting results yet choose to ignore the greater risk of atherosclerosis Tasigna chemotherapy poses

Tuesday, October 16, 2018 - Novartis has recently repackaged Tasigna to include the recent findings that the drug is so effective in treating CML that some patients can stop chemotherapy treatments altogether. Rather then further promoting the anti-cancer drug the company may have opted to instead warn oncologists that their patient may face an elevated risk of developing atherosclerosis, a deadly, irreversible and permanent form of coronary artery disease.

Studies of Tasigna now show that up to one-third of all patients given the drug could face the need to undergo coronary bypass surgery to unclog vital arteries destroyed by Tasigna toxicity. The very real atherosclerosis risks of Tasigna were underscored in a talk given by Surabhi Dangi-Garimella, Ph.D. at the Conferences of the American Society of Hematology, the results of which were published on the AJMC website on December 10, 2017. At the meeting, physicians shared the latest information about the cardiovascular toxicities including atherosclerosis-related side effects of tyrosine kinase inhibitors (TKIs) one of which is market leader Tasigna.

Ceasing usage of the TKI drugs was urged not so much for its cancer-fighting effectiveness but more for its life-threatening side effects that include "off-target effects, severe adverse events, including pulmonary arterial hypertension (PAH) and pleural effusion, cardiovascular toxicity, contraindication in pregnant women, effects on fertility, and growth alteration in children."

Dr. Javid Moslehi, MD, of Vanderbilt School of Medicine, Nashville, Tennesse spoke at the conference about the cardiovascular toxicities of TKI's. Moslehi's practice involves managing a patient's cancer treatment toxic side effects. He has found that the adverse side effects of Tasigna include "heart failure and coronary artery disease, cardiomyopathy, myocarditis, atherosclerosis, arrhythmia, and atrial fibrillation." "Dr. Moslehi pointed out that oncologists have mostly ignored the cardiovascular effects due to a lack of education on the subject. The doctor also stressed that cardiovascular testing of patients before, during and after treatments with Tasigna is essential to identifying a developing heart condition and to promote the "the ABCDE steps for heart and vascular wellness."

In spite of the fact that Tasigna is extremely effective in fighting CML, most patients cannot tolerate Tasigna treatments for very long without developing an atherosclerosis-related condition. Post-market Tasigna studies found that one in five Tasigna patients develop atherosclerosis to some degree or another. Atherosclerosis is the roughening of the otherwise smooth inner lining of the arteries causing the blood's fatty component to stick to and accumulate within the artery's inner walls. Atherosclerosis normally takes years to develop from a poor diet but can occur in mere weeks after taking Tasigna. Rapid-onset atherosclerosis causes tissue death in the extremities due to a decreased blood supply. Tasigna atherosclerosis is usually treated with amputation. Heart attack and stroke have also been reported when a chunk of plaque breaks free and becomes lodged in the smaller arteries leading to the brain and heart. The result can be severe paralysis and even instant death. Tasigna atherosclerosis lawsuits against the Swiss drugmaker Novartis are the best means for individual consumers to hold the pharmaceutical giant accountable.

More Recent Tasigna Atherosclerosis Lawsuit News:

• Tasigna Patients Are Warned of The Risk of Sudden Death | 5/13/2019
• Tasigna's Atherosclerosis Risk Is Well-Documented By Researchers For Peer-Reviewed Medical Publications | 5/8/2019
• Tasigna's Atherosclerosis Side Effect Is Not Forgotten | 4/17/2019
• Trying Tasigna As A Last Resort May Make Sense To Terminally Ill Cancer Patients | 4/12/2019
• Novartis Claim Tasigna Can Help Parkinson's Patients is Met With Skepticism | 4/4/2019
• Novartis Failed To Warn American Doctors Who In Turn Failed To Warn Patients of Tasigna's Atherosclerosis Risks | 3/20/2019
• Tasigna Is Being Repurposed To Treat Parkinson's Disease | 3/14/2019
• Some Patient Can Cease Taking Tasigna But They May Have Already Developed Atherosclerosis | 3/12/2019
• Health Experts Warn of Potentially Deadly Tasigna Drug Interactions | 3/5/2019
• The Potential To Someday Stop Tasigna Treatments Should Not Be An Incentive To Take The Drug | 2/28/2019
• Tasigna Studies Show The Drug Should Be Taken As A Last Resort | 2/24/2019
• Cancer Doctors and Medical Websites Should Take Tasigna's Atherosclerosis Risks More Seriously | 2/18/2019
• The FDA May Be Putting Children's Lives In Danger By Ignoring Tasigna's Atherosclerosis Risk | 2/12/2019
• The FDA May Have Overlooked Tasigna's Atherosclerosis Side Effect When Approving its Usage by Children | 2/5/2019
• Children With Cancer May Now Start Taking Tasigna | 1/31/2019
• Studies Reported by Leading Experts Focus on Tasigna Toxicity | 1/25/2019
• Novartis Has a History of Deceptive Sale Practices That Taints Their Credibility | 1/22/2019
• Novartis Changes Tasigna's Label But Not Its Toxicity | 1/16/2019
• Tasigna Doctors May Be Ignoring Atherosclerosis Risks | 1/11/2019
• Cancer Doctors Prescribing Tasigna Should Be Trained Like Heart Specialists | 1/8/2019
• Tasigna is Effective in Treating Chronic Myeloid Leukemia | 1/1/2019
• Early Warning Signs of Chronic Myeloid Leukemia (CML) | 12/5/2018
• CML Patients in Remission May Discontinue Taking Tasigna | 12/1/2018
• Tasigna's Atherosclerosis Warnings is Rarely Seen by Cancer Patients | 11/28/2018
• Novartis' Failure to Warn the FDA May Have Led to Atherosclerosis in As Many As One in Four Tasigna Patients | 11/12/2018
• Novartis Highlights Tasigna's Effectiveness yet Downplays The Drug's Deadly Side Effects | 11/8/2018
• Novartis Takes Advantage of Tasigna's Catch 22 | 10/30/2018
• Tasigna Atherosclerosis Ignored by Novartis Celebrity Spokesperson | 10/24/2018
• The FDA Atherosclerosis Warning Came Too Late for Tasigna Patients in the United States | 10/8/2018
• One-Third of Tasigna Patients Could Face Coronary Bypass Surgery | 10/4/2018
• Billion Dollar Fines Are Just a Cost of Doing Business For Novartis | 10/2/2018
• Cancer Patients Should View Novartis' New Tasigna Label With Scepticism | 9/28/2018
• Novartis Boasts of Tasigna's Effectiveness While Ignoring the Atherosclerosis Side Effects | 9/27/2018
• Tasigna May Be One Of The Most Deadly Drugs On The Market Today | 9/25/2018
• NBA Star's Arterial Blockage May Have Been Caused by Taking Tasigna | 9/22/2018
• Taxpayers Saved Billions By Novartis AG Whistleblower | 9/20/2018
• Tasigna Carries The Unacceptable Risk of Developing Atherosclerosis and Amputation | 9/19/2018
• Tasigna's Cancer-Fighting Success May Be Tempered By The Risk Of Sudden Death | 9/17/2018
• Novartis Pulled No Punches In Warning Canadians About The Atherosclerosis Related Side effects Of Tasigna Yet Said Nothing To Warn Cancer Patients In The United States. | 9/11/2018
• Novartis is a Repeat Offender for Fraudulent Drug Marketing | 8/29/2018
• Peripheral Artery Disease Plagues Tasigna Patients | 8/27/2018
• Patients Could Have Benefited From Gleevec's Generic Alternative | 8/21/2018
• Novartis/Tasigna Lawsuit May Seek Punitive Damages | 8/17/2018
• Tasigna Atherosclerosis Trial Set to Proceed | 8/14/2018
• Medical Websites Ignore Tasigna's Risks | 8/10/2018
• Novartis haste in rushing Tasigna to market has cost patients their lives | 8/8/2018
• Tasigna's Side Effects Require Special Attention From Prospective Patients | 8/6/2018
• Novartis Whistleblower Receives $12 Million For His Efforts | 7/31/2018
• Tasigna Atherosclerosis Hidden From Americans | 7/30/2018
• Gleevec Was a Cancer-Curing Miracle Drug | 7/26/2018
• Tasigna Stroke Victim's Trial to Proceed in Florida | 7/24/2018
• Novartis Employee Blows Whistle on Tasigna Fraud and Others | 7/20/2018
• Tasigna Side Effects Are Worse Than Cancer | 7/18/2018
• Tasigna Cancer Medication Carries More Risks Than Others | 7/11/2018
• Specialty Pharmacists Bribed to Prescribe Tasigna | 7/6/2018
• Novartis Billion-Dollar Fine for Fraudulent Marketing Tactics | 7/2/2018
• Tasigna Black Box Warning Addendum | 6/29/2018
• Tasigna Replaced Gleevec and Patients Suffered | 6/25/2018
• Specialty Pharmacists Selling Tasigna Compromised Ethical Standards | 6/20/2018
• US Department of Justice Fines Novartis One Billion Dollars | 6/13/2018
• Tasigna Sudden Death Warning | 6/11/2018
• Tasigna Cancer Treatment Poses Scary Risks | 6/7/2018
• Novartis Fraudulent Marketing Deception | 5/29/2018
• Tasigna Atherosclerosis Warning Never Made it to the US | 5/25/2018
• Novartis Tasigna Anti-Cancer Drug Has Side Effects That Include Sudden Death | 5/22/2018
• Tasigna Replaced Gleevec Under Fraudulent Circumstance | 5/18/2018
• Novartis Held Accountable For Concealing Tasigna Atherosclerosis Risk | 5/15/2018
• Tasigna Chemotherapy Carries a Sudden Death Warning | 5/10/2018
• Novartis Warns That Tasigna Can Cause Atherosclerosis | 5/6/2018
• Tasigna Poses Atherosclerosis Amputations Risk | 5/3/2018
• Tasigna Rushed to Market to Replace Gleevec | 12/29/2017
• Whistleblower Saves American Taxpayers Millions | 12/22/2017
• Gleevec-the Novartis AG Wonder Drug | 12/20/2017
• Tasigna Warnings | 12/18/2017
• Tasignas Black Box Warning Links The Drug To Atherosclerosis | 12/15/2017
• Novartis Fails To Warn The U.S. Medical Community About The Side Effects of Tasigna | 12/11/2017
• Tasigna Replaces Gleevec as the Novartis AGs Signature Anti-Cancer Chemotherapy Drug | 12/6/2017
• The Unmistakable Signs of Peripheral Artery Disease | 12/1/2017
• Whistleblower Causes Public Alert to Tasigna Side Effects | 11/27/2017
• The Estate of a California Man is Suing Novartis | 11/20/2017
• Ex-Novartis Salesmanager Blows The Whistle On Illegal Drug Marketing | 11/13/2017
• U.S. Cancer Patients Receive Tasigna Atherosclerosis Warning | 11/6/2017
• Novartis Marketed Tasigna to Replace Gleevec | 11/3/2017
• Leukemia Patients May Suffer From Heart Disease as Well | 10/30/2017
• Novartis' Potentially Misleading Drug Marketing Campaign | 10/23/2017
• Health Canada Issued a Tasigna Health Warning In 2013 | 10/16/2017
• Lawsuits Allege Novartis Was Aware of The Side Effects of Tasigna Yet Failed to Warn The American Public | 10/9/2017
• Tasigna Chemotherapy Atherosclerosis-related Side Effects | 10/2/2017
• The Onder Law Firm Seeks to Hold Novartis Accountable for the Suffering Tasigna Has Caused Families | 9/29/2017
• Novartis Fails to Warn About Tasigna Atherosclerosis | 9/22/2017
• Side Effects of Tasigna Cancer Drug Include Atherosclerosis and Peripheral Artery Disease | 9/15/2017
• Novartis Put Profits Ahead of Patients | 9/7/2017
• Novartis Failed to Warn the American Medical Community of the Side Effects of Tasigna | 9/1/2017
• Atherosclerosis Linked to Tasigna Anti Cancer Drug | 8/18/2017
• You Can Sue Novartis If You Have Developed Atherosclerosis-Related Conditions After Taking Tasigna | 8/11/2017
• Who Can Be Considered A Tasigna Victim | 8/4/2017
• Novartis AG makers of Tasigna Failed to Warn Public of the Dangerous Side Effects | 7/14/2017
• Tasigna Anti Cancer Drug Lawsuit | 7/7/2017
• Tasigna Drug Warning for Peripheral Arterial Disease | 6/30/2017
• Tasigna Cancer Treatment Drug Lawsuit | 6/26/2017
• Novartis International AG Lawsuits | 6/23/2017
• Lawsuits Against Novartis International AG Makers of Tasigna | 6/21/2017
• Tasigna Peripheral Artery Disease Warning | 6/19/2017
• Tasigna Lawsuits Against Drug Makers Novartis | 6/16/2017
• Atherosclerosis of the Aorta Linked to Tasigna Anti-Cancer Drug | 6/12/2017
• Makers of Tasigna Leukemia Drug Lawsuit | 6/9/2017
• Tasigna a Cancer Drug Treatment | 6/5/2017
• Tasigna Peripheral Arterial Disease | 6/1/2017

Lawyers for Tasigna Atherosclerosis Lawsuits

Attorneys handling Tasigna lawsuits for leukemia, non-Hodgkin lymphoma, and multiple myeloma offer free, no-obligation case review for individuals and families who believe they may have grounds to file a Tasigna lawsuit. Working on a contingency basis, these attorneys are committed to never charging legal fees unless they win compensation in your Tasigna lawsuit. The product liability litigators handling Roundup claims at the Onder Law Firm have a strong track record of success in representing families harmed by dangerous drugs and consumer products.